Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The investigators will conduct a 6-week, randomized, double-blind, placebo-controlled trial
of celecoxib as an add-on treatment to the mood stabilizer among women with bipolar I or II
postpartum depression. Women who are taking a mood stabilizer for treatment of bipolar
disorder in the postpartum treatment will receive either a placebo or celecoxib add-on
treatment. Patients will be monitored regularly to assess psychiatric symptoms and side
effects. The investigators aim to evaluate the potential antidepressant effect of celecoxib
in bipolar postpartum depression.